These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 17239709)

  • 21. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.
    Sabatine MS; Morrow DA; Jablonski KA; Rice MM; Warnica JW; Domanski MJ; Hsia J; Gersh BJ; Rifai N; Ridker PM; Pfeffer MA; Braunwald E;
    Circulation; 2007 Mar; 115(12):1528-36. PubMed ID: 17372173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
    Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
    Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
    Li JJ; Fang CH
    Med Hypotheses; 2004; 62(4):499-506. PubMed ID: 15050096
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
    Davidson MH; Stein EA; Bays HE; Maki KC; Doyle RT; Shalwitz RA; Ballantyne CM; Ginsberg HN;
    Clin Ther; 2007 Jul; 29(7):1354-67. PubMed ID: 17825687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-sensitivity C-reactive protein in Japanese patients with type 2 diabetes.
    Tajiri Y; Mimura K; Umeda F
    Obes Res; 2005 Oct; 13(10):1810-6. PubMed ID: 16286529
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pioglitazone administration decreases cardiovascular disease risk factors in insulin-resistant smokers.
    Abbasi F; Farin HM; Lamendola C; McGraw L; McLaughlin T; Reaven GM
    Metabolism; 2008 Aug; 57(8):1108-14. PubMed ID: 18640389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.
    Rosenstock J; Kim SW; Baron MA; Camisasca RP; Cressier F; Couturier A; Dejager S
    Diabetes Obes Metab; 2007 Mar; 9(2):175-85. PubMed ID: 17300593
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-sensitivity C-reactive protein may be an indicator of the development of atherosclerosis in myocardial bridging.
    Duygu H; Zoghi M; Nalbantgil S; Ozerkan F; Cakir C; Ertas F; Yuksek U; Akilli A; Akin M; Ergene O
    Int J Cardiol; 2008 Feb; 124(2):267-70. PubMed ID: 17395309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Variability of C-reactive protein levels among patients with stable coronary artery disease and on statin therapy.
    Blum A; Costello R; Samsel L; Zalos G; McCoy P; Csako G; Waclawiw MA; Cannon RO
    Isr Med Assoc J; 2009 Oct; 11(10):602-5. PubMed ID: 20077946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL.
    van den Akker JM; Bredie SJ; Diepenveen SH; van Tits LJ; Stalenhoef AF; van Leusen R
    J Nephrol; 2003; 16(2):238-44. PubMed ID: 12768071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. C-reactive protein, insulin resistance and risk of cardiovascular disease: a population-based study.
    Jeppesen J; Hansen TW; Olsen MH; Rasmussen S; Ibsen H; Torp-Pedersen C; Hildebrandt PR; Madsbad S
    Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):594-8. PubMed ID: 18753952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome.
    Esposito K; Ciotola M; Carleo D; Schisano B; Saccomanno F; Sasso FC; Cozzolino D; Assaloni R; Merante D; Ceriello A; Giugliano D
    Diabetes Care; 2006 May; 29(5):1071-6. PubMed ID: 16644639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of pioglitazone on lipid and lipoprotein metabolism.
    Betteridge DJ
    Diabetes Obes Metab; 2007 Sep; 9(5):640-7. PubMed ID: 17697057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The anti-inflammatory effects of exercise training in patients with type 2 diabetes mellitus.
    Kadoglou NP; Iliadis F; Angelopoulou N; Perrea D; Ampatzidis G; Liapis CD; Alevizos M
    Eur J Cardiovasc Prev Rehabil; 2007 Dec; 14(6):837-43. PubMed ID: 18043308
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels.
    Pearson T; Ballantyne C; Sisk C; Shah A; Veltri E; Maccubbin D
    Am J Cardiol; 2007 Jun; 99(12):1706-1713. PubMed ID: 17560879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High sensitive C-reactive protein, adiponectin, and urine albumin excretion rate in Chinese coronary artery disease patients with different glucose tolerance status.
    Gui MH; Hong J; Lü AK; Chen Y; Shen WF; Li XY; Ning G
    Chin Med J (Engl); 2008 Dec; 121(24):2509-16. PubMed ID: 19187587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma concentrations of C-reactive protein and total homocysteine in relation to the severity and risk factors for cerebrovascular disease.
    Youssef MY; Mojiminiyi OA; Abdella NA
    Transl Res; 2007 Sep; 150(3):158-63. PubMed ID: 17761368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of pioglitazone versus metformin on cardiovascular risk markers in type 2 diabetes.
    Genovese S; De Berardis G; Nicolucci A; Mannucci E; Evangelista V; Totani L; Pellegrini F; Ceriello A
    Adv Ther; 2013 Feb; 30(2):190-202. PubMed ID: 23359066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simvastatin exerts its anti-inflammatory effect in hypercholesterolaemic patients by decreasing the serum levels of monocyte chemoattractant protein-1.
    Rallidis LS; Hamodraka ES; Fountoulaki K; Moustogiannis G; Zolindaki MG; Kremastinos DT
    Int J Cardiol; 2008 Feb; 124(2):271-2. PubMed ID: 17399814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low dose rofecoxib, inflammation and prostacyclin synthesis in acute coronary syndromes.
    Kuklińska AM; Musiał WJ; Kamiński KA; Kralisz P; Modrzejewski W; Sobkowicz B; Dobrzycki S; Stec S; Wojtkowska I
    Rocz Akad Med Bialymst; 2005; 50():339-42. PubMed ID: 16358997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.